SEARCH

SEARCH BY CITATION

References

  • 1
    Liebreich R. Ophthalmoskopishe Notizen: Ueber die Farbe des Augengrundes. Albrecht Von Graefes Arch Ophthalmol 1855; 1: 33356.
  • 2
    Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountain Eye Study. Arch Ophthalmol 1996; 114: 12437.
  • 3
    Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 13341.
  • 4
    Rogers S, McIntosh RL, Cheung N et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 31319.
  • 5
    McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 111323.
  • 6
    Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90: 45874.
  • 7
    Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 108795.
  • 8
    Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol 1990; 228: 20117.
  • 9
    Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 48691.
  • 10
    McAllister IL, Gillies M, Smithies L et al. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthamology 2010; 117: 95465.
  • 11
    Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: a prospective study of 175 cases. Ophthalmology 1996; 103: 55160.
  • 12
    Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981; 79: 371442.
  • 13
    Taylor AW, Sehu W, Williamson TH, Lee WR. Morphometric assessment of the central retinal artery and vein in the optic nerve head. Can J Ophthalmol 1993; 28: 3204.
  • 14
    Williamson TH. A ‘throttle’ mechanism in the central retinal vein in the region of the lamina cribrosa. Br J Ophthalmol 2007; 91: 11903.
  • 15
    Kang MH, Balaratnasingam C, Yu PK et al. Morphometric characteristics of central retinal artery and vein endothelium in the normal human optic nerve head. Invest Ophthalmol Vis Sci 2011; 52: 135967.
  • 16
    Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493519.
  • 17
    Beaumont PE, Kang HK. Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 2000; 118: 135763.
  • 18
    Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 1992; 99: 50914.
  • 19
    The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 54554.
  • 20
    Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 12437.
  • 21
    Koizumi H, Ferrara DC, Brué C, Spaide RF. Central retinal vein occlusion case-control study. Am J Ophthalmol 2007; 144: 85863.
  • 22
    Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 6177.
  • 23
    Cheung N, Klein R, Wang JJ et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008; 49: 4297302.
  • 24
    Browning DJ, Fraser CM. Retinal vein occlusions in patients taking warfarin. Ophthalmology 2004; 111: 1196200.
  • 25
    Mruthyunjaya P, Wirostko WJ, Chandrashekhar R et al. Central retinal vein occlusion in patients treated with long-term warfarin sodium (coumadin) for anticoagulation. Retina 2006; 26: 28591.
  • 26
    Nash GB. Blood rheology and ischaemia. Eye 1991; 5: 1518.
  • 27
    Ring CP, Pearson TC, Sanders MD, Wetherley-Mein G. Viscosity and retinal vein thrombosis. Br J Ophthalmol 1976; 60: 397410.
  • 28
    Trope GE, Lowe GD, McArdle BM et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983; 67: 13742.
  • 29
    Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996; 80: 2038.
  • 30
    Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 806.
  • 31
    Glacet-Bernard A, Chabanel A, Lelong F, Samama MM, Coscas G. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 1994; 101: 14837.
  • 32
    Sofi F, Mannini L, Marcucci R et al. Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost 2007; 98: 121519.
  • 33
    Francis PJ, Stanford MR, Graham EM. Dehydration is a risk factor for central retinal vein occlusion in young patients. Acta Ophthalmol Scand 2003; 81: 41516.
  • 34
    Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol 2005; 139: 1812.
  • 35
    Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 6404.
  • 36
    Brown BA, Marx JL, Ward TP et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109: 28790.
  • 37
    Weger M, Stanger O, Deutschmann H et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 28690.
  • 38
    Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 113650.
  • 39
    Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006; 47: 406771.
  • 40
    McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009; 116: 177887.
  • 41
    Cobo-Soriano R, Sánchez-Ramón S, Aparicio MJ et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128: 72532.
  • 42
    Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina 2003; 23: 48690.
  • 43
    Ilhan F, Celiker U, Godekmerdan A, Kan E. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Arch Med Res 2005; 36: 3725.
  • 44
    Di Capua M, Coppola A, Albisinni R et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis 2010; 30: 1622.
  • 45
    Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Throm Haemost 2005; 93: 10216.
  • 46
    Fegan CD. Central retina vein occlusion and thrombophilia. Eye 2002; 16: 98106.
  • 47
    A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 143444.
  • 48
    Leoncini G, Bruzzese D, Signorello MG et al. Platelet activation by collagen is increased in retinal vein occlusion. Throm Haemost 2007; 97: 21827.
  • 49
    Yamamoto T, Kamei M, Yokoi N, Yasuhara T, Tei M, Kinoshita S. Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering. Am J Ophthalmol 2004; 138: 80917.
  • 50
    Arroyo JG, Dastgheib K, Hatchell DL. Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. Jpn J Ophthalmol 2001; 45: 35962.
  • 51
    Kohner EM, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in the treatment of central retinal vein occlusion: a controlled trial. Trans Ophthalmol Soc UK 1974; 94: 599603.
  • 52
    Kohner EM, Pettit JE, Hamilton AM, Bulpitt CJ, Dollery CT. Streptokinase in central retinal vein occlusion: a controlled clinical trial. BMJ 1976; 1: 5503.
  • 53
    Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc 1996; 94: 471504.
  • 54
    Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30: 42734.
  • 55
    Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 2000; 84: 60913.
  • 56
    Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001; 108: 224957.
  • 57
    Bynoe LA, Hutchins RK, Lazarus HS, Friedberg MA. Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons. Retina 2005; 25: 62532.
  • 58
    Vasco-Posada J. Modification of the circulation in the posterior pole of the eye. Ann Ophthalmol 1972; 4: 4859.
  • 59
    Dev S, Buckley EG. Optic nerve sheath decompression for progressive central retinal vein occlusion. Ophthalmic Surg Lasers 1999; 30: 1814.
  • 60
    Rodríguez A, Rodríguez FJ, Betancourt F. Presumed occlusion of posterior ciliary arteries following central retinal vein decompression surgery. Arch Ophthalmol 1994; 112: 546.
  • 61
    Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001; 21: 40815.
  • 62
    Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006; 26: 297305.
  • 63
    Hasselbach HC, Ruefer F, Feltgen N et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Arch Clin Exp Ophthalmol 2007; 245: 114556.
  • 64
    Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol 2003; 136: 81419.
  • 65
    Martínez-Jardón CS, Meza-de Regil A, Dalma-Weiszhausz J et al. Radial optic neurotomy for ischaemic central vein occlusion. Br J Ophthalmol 2005; 89: 55861.
  • 66
    Horio N, Horiguchi M. Retinal blood flow and macular edema after radial optic neurotomy for central retinal vein occlusion. Am J Ophthalmol 2006; 141: 314.
  • 67
    Hayreh SS. Radial optic neurotomy for central retinal vein occlusion [letter]. Retina 2002; 22: 3747.
  • 68
    Garcia-Arumi J, Boixadera A, Martinez-Castillo V, Castillo R, Dou A, Corcostegui B. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003; 121: 138591.
  • 69
    Nomoto H, Shiraga F, Yamaji H et al. Evaluation of radial optic neurotomy for central retinal vein occlusion by indocyanine green videoangiography and image analysis. Am J Ophthalmol 2004; 138: 61219.
  • 70
    Williamson TH, Poon W, Whitefield L, Strothoudis N, Jaycock P. A pilot study of pars plana vitrectomy, intraocular gas, and radial neurotomy in ischaemic central retinal vein occlusion. Br J Ophthalmol 2003; 87: 11269.
  • 71
    Schneider U, Inhoffen W, Grisanti S, Bartz-Schmidt KU. Characteristics of visual field defects by scanning laser ophthalmoscope microperimetry after radial optic neurotomy for central retinal vein occlusion. Retina 2005; 25: 70412.
  • 72
    Tsujikawa A, Hangai M, Kikuchi M, Ishida K, Kurimoto Y. Visual field defect after radial optic neurotomy for central retinal vein occlusion. Jpn J Ophthalmol 2006; 50: 15860.
  • 73
    Yamamoto S, Takatsuna Y, Sato E, Mizunoya S. Central retinal artery occlusion after radial optic neurotomy in a patient with central retinal vein occlusion. Am J Ophthalmol 2005; 139: 2067.
  • 74
    Takaya K, Suzuki Y, Nakazawa M. Massive hemorrhagic retinal detachment during radial optic neurotomy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 2657.
  • 75
    Strauss RW, Priglinger SG, Alge CS, Grueterich M, Haritoglou C. Persistent serous retinal detachment after radial optic neurotomy [letter]. Clin Experiment Ophthalmol 2006; 34: 71820.
  • 76
    McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995; 113: 45662.
  • 77
    McAllister IL, Douglas JP, Constable IJ, Yu DY. Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol 1998; 126: 21929.
  • 78
    Fong CS, Barry C, McAllister IL. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion. Clin Experiment Ophthalmol 2009; 37: 48589.
  • 79
    Tsui I, Kaines A, Havunjian MA et al. Ischaemic index and neovascularisation in central retinal vein occlusion. Retina 2011; 31: 10510.
  • 80
    Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 142533.
  • 81
    Hansen LL, Danisevskis P, Arntz HR, Hovener G, Wiederholt M. A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 1985; 69: 10816.
  • 82
    Hanson LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73: 8959.
  • 83
    Luckie AP, Wroblewski JJ, Hamilton P et al. A randomised prospective study of outpatient haemodilution for central retinal vein obstruction. Aust NZ J Ophthalmol 1996; 24: 22332.
  • 84
    Glacet-Bernard A, Atassi M, Fardeau C et al. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol 2011; 249: 50512.
  • 85
    Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama M. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994; 118: 4219.
  • 86
    Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 11559.
  • 87
    Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 30915.
  • 88
    McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009; 147: 83846.
  • 89
    The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 110114.
  • 90
    Ramchandran RS, Fekrat S, Stinnett SS, Jaffe GJ. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol 2008; 146: 28591.
  • 91
    Haller JA, Bandello F, Belfort R et al. For the OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 113446.
  • 92
    Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998; 105: 41216.
  • 93
    Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 3369.
  • 94
    Iturralde D, Spaide RF, Meyerle CB. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 27984.
  • 95
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 1419.
  • 96
    Wroblewski JJ, Wells JA, Adamis AP et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127: 37480.
  • 97
    Brown DM, Campochiaro PA, Singh RP et al. For the CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 112433.
  • 98
    Campochiaro PA, Brown DM, Awh CC et al. Sustained benefits from Ranibizumab for macular edema following central retinal vein occlusion: twelve month outcomes of a phase III study. Ophthalmology 2011; 118: 20419.